Volume 13, Issue 3 (9-2025)                   JoMMID 2025, 13(3): 177-184 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khan S M, Amin U, Masoodi T, Miraj T, Qadri M I, Pirzada M et al . Prevalence and Antimicrobial Susceptibility Profile of Salmonella spp. Isolated from Blood Cultures of Patients with Suspected Enteric Fever at a Specialized Laboratory in North India. JoMMID 2025; 13 (3) :177-184
URL: http://jommid.pasteur.ac.ir/article-1-727-en.html
Prevalence and Antimicrobial Susceptibility Profile of Salmonella spp. Isolated from Blood Cultures of Patients with Suspected Enteric Fever at a Specialized Laboratory in North India
Shoaib Mohmad Khan , Umara Amin * , Tamkeen Masoodi , Tariq Miraj , M. I. Qadri , Mudasir Pirzada , Waseem Ahmad Rather
Department of Microbiology, Dr. Qadri’s Hematology Centre & Clinical Laboratory, Srinagar, Jammu & Kashmir, 190010, India
Abstract:   (328 Views)
Introduction: Enteric fever, caused by Salmonella enterica serovars Typhi and Paratyphi A, is a prevalent infection in developing countries. Although highly endemic in India, data on the prevalence and antimicrobial resistance patterns of this pathogen in Kashmir remain scarce. Therefore, this study aimed to determine the prevalence and antimicrobial susceptibility profile of Salmonella isolates from blood cultures of patients with suspected enteric fever. Methods: A total of 970 blood culture samples from patients with suspected enteric fever were processed at Dr. Qadri’s Hematology Centre & Clinical Laboratory, Srinagar, between October 2022 and September 2024. Samples were inoculated into the BacT/ALERT® culture media. Positive cultures were subcultured on standard agar plates, and the resulting isolates were identified and subjected to antimicrobial susceptibility testing using the VITEK® 2 system according to the latest Clinical and Laboratory Standards Institute (CLSI) guidelines. Results: Of the 970 blood cultures processed, 37 (3.8%) were positive for Salmonella spp., with 23 (62.2%) isolates identified as S. Typhi and 14 (37.8%) as S. Paratyphi A. All isolates showed 100% susceptibility to cefepime, piperacillin/tazobactam, carbapenems, azithromycin, tetracyclines, co-trimoxazole, and polymyxins. Susceptibility to ceftriaxone and tigecycline was 97.3%. In contrast, susceptibility rates were markedly low for the fluoroquinolones ciprofloxacin (2.7%) and levofloxacin (5.4%). Furthermore, no multidrug-resistant (MDR) isolates were detected in this study. Conclusions: This study demonstrates that S. enterica remains a significant cause of bloodstream infections in this resource-limited setting. However, the high prevalence of fluoroquinolone resistance, despite the absence of MDR strains, represents the primary therapeutic challenge in managing these infections. Therefore, extensive surveillance, enhanced diagnostics, and treatment protocols guided by antimicrobial susceptibility testing (AST) reports are crucial to optimize patient outcomes and combat emerging resistance in the region.
Keywords: Antimicrobial resistance, Salmonella, Fluoroquinolone resistance, North India, Minimum inhibitory concentration
Full-Text [PDF 806 kb]   (49 Downloads)    
Type of Study: Original article | Subject: Infectious diseases and public health
Received: 2025/04/13 | Accepted: 2025/09/10 | Published: 2025/12/2
References
1. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's principles and practices of infectious diseases, 9th edn. Philadelphia,PA: Elsevier, 2019.
2. Deen J, von Seidlein L, Andersen F, Elle N, White NJ, Lubell Y. 2012. Community acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infect Dis 12:480-487. [DOI:10.1016/S1473-3099(12)70028-2] [PMID]
3. Meiring, J.E.; Shakya, M.; Khanam, F.; Voysey, M.; Phillips, M.T.; Tonks, S.; Thindwa, D.; Darton, T.C.; Dongol, S.; Karkey, A.; et al. Burden of enteric fever at three urban sites in Africa and Asia: A multicentre population-based study. Lancet Glob. Health 2021, 9, e1688-e1696. [DOI:10.1016/S2214-109X(21)00370-3] [PMID]
4. Crump JA, Luby SP, Mintz ED. 2004. The global burden of typhoid fever. Bull World Health Organ 82:346-353.
5. Osler W. 1912. The principles and practice of medicine: designed for the use of practitioners and students of medicine, 8th ed D. Appleton and Company, New York, NY.
6. Stuart BM, Pullen RL. 1946. Typhoid: clinical analysis of 360 cases. Arch Intern Med 78:629 - 661. [DOI:10.1001/archinte.1946.00220060002001] [PMID]
7. Crump, J.A.; Sjölund-Karlsson, M.; Gordon, M.A.; Parry, C.M. Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections. Clin. Microbiol. Rev. 2015, 28, 901-937. [DOI:10.1128/CMR.00002-15] [PMID] [PMCID]
8. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. 2002. Typhoid fever. N Engl J Med 347:1770-1782. [DOI:10.1056/NEJMra020201] [PMID]
9. Walia M, Gaind R, Mehta R, Paul P, Aggarwal P, Kalaivani M. 2005. Current perspectives of enteric fever: a hospital-based study from India. Ann Trop Paediatr 25:161-174. [DOI:10.1179/146532805X58085] [PMID]
10. Caygill CP, Braddick M, Hill MJ, Knowles RL, Sharp JC. 1995. The association between typhoid carriage, typhoid infection and subsequent cancer at a number of sites. Eur J Cancer Prev 4:187-193. [DOI:10.1097/00008469-199504000-00010] [PMID]
11. United Nations. 2014. Millenium development goal.http://www.un.org/millenniumgoals/.
12. World Health Organization Typhoid vaccines: WHO position paper, March 2018 - Recommendations. Vaccine. 2019 Jan 07;37(2):214-216. [DOI:10.1016/j.vaccine.2018.04.022] [PMID]
13. Baker S, Favorov M, Dougan G. Searching for the elusive typhoid diagnostic. BMC Infect Dis. 2010;10:45. [DOI:10.1186/1471-2334-10-45] [PMID] [PMCID]
14. Wain J, Hendriksen RS, Mikoleit ML, et al. Typhoid fever. Lancet. 2015;385:1136-1145. [DOI:10.1016/S0140-6736(13)62708-7] [PMID]
15. Brooks WA, Hossain A, Goswami D, et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis. 2005;11:326-329. [DOI:10.3201/eid1102.040422] [PMID] [PMCID]
16. Cockerill FR, Wilson JW, Vetter EA, Goodman KM, Torgerson CA, Harmsen WS, Schleck CD, Ilstrup DM, Washington JA, Wilson WR. 2004. Optimal testing parameters for blood cultures. Clin Infect Dis 38: 1724-1730. [DOI:10.1086/421087] [PMID]
17. Woodward TE, Smadel JE. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann Intern Med. 1948;29:131-134. [DOI:10.7326/0003-4819-29-1-131] [PMID]
18. Kidgell C, Reichard U, Wain J, et al. Salmonella typhi, the causative agent of typhoid fever, is approximately 50,000 years old. Infect Genet Evol. 2002;2:39-45. [DOI:10.1016/S1567-1348(02)00089-8] [PMID]
19. Rowe B, Ward LR, Threlfall EJ. 1997. Multidrug-resistant Salmonella Typhi: a worldwide epidemic. Clin Infect Dis 24:S106-S109. [DOI:10.1093/clinids/24.Supplement_1.S106] [PMID]
20. Threlfall EJ, Ward LR. 2001. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype Typhi, United Kingdom. Emerg Infect Dis 7:448-450. [DOI:10.3201/eid0703.017315]
21. Ahmed D, Hoque A, Mazumder R, Nahar K, Islam N, Gazi SA, Hossain MA. 2012. Salmonella enterica serovar Typhi strain producing extended-spectrum beta-lactamases in Dhaka, Bangladesh. JMedMicrobiol 61:1032-1033. [DOI:10.1099/jmm.0.044065-0] [PMID]
22. Hughes MJ, Birhane MG, Dorough L, et al. Extensively Drug-Resistant Typhoid Fever in the United States. Open Forum Infect Dis. 2021 Dec. 8(12):ofab572. [DOI:10.1093/ofid/ofab572] [PMID] [PMCID]
23. WHO Guidelines on Drawing Blood: Best Practices in Phlebotomy. Geneva: World Health Organization; 2010.
24. CLSI. Principles and Procedures for Blood Cultures. 2nd ed. CLSI guideline M47. Clinical and Laboratory Standards Institute; 2022
25. Wilson ML, Mirrett S, Reller LB, et al. Recovery of clinically important microorganisms from the BacT/ ALERT blood culture system does not require testing for 7 days. Diagn Microbiol Infect Dis. 1993;16(1):31-34 [DOI:10.1016/0732-8893(93)90127-S] [PMID]
26. Isenberg, H.D. Clinical Microbiology Procedures Handbook, 3rd ed.; ASM Press: Washington, DC, USA, 2007.
27. Clinical and Laboratory Standards Institute® (CLSI). M 100 Performance Standards for Antimicrobial Susceptibility Testing, 33rd edition. 2023.
28. Mogasale, V.; Maskery, B.; Ochiai, R.L.; Lee, J.S.; Ramani, E.; Kim, Y.E.; Park, J.K.; Wierzba, T.F. Burden of typhoid fever in low-income and middle-income countries: A systematic, literature-based update with risk-factor adjustment. Lancet Glob. Health 2014, 2, e570-e580. [DOI:10.1016/S2214-109X(14)70301-8] [PMID]
29. Fatima, M.; Kumar, S.; Hussain, M.; Memon, N.M.; Vighio, A.; Syed, M.A.; Chaudhry, A.; Hussain, Z.; Baig, Z.I.; Baig, M.A.; et al. Morbidity and Mortality Associated with Typhoid Fever Among Hospitalized Patients in Hyderabad District, Pakistan, 2017-2018: Retrospective Record Review. JMIR Public Health Surveill. 2021, 7, e27268. [DOI:10.2196/27268] [PMID] [PMCID]
30. Bhumbla U, Chaturvedi P, Jain S. Prevalence of Salmonella typhi in among febrile patients in a tertiary care hospital of South West Rajasthan. J Family Med Prim Care 2022;11:2852-5. [DOI:10.4103/jfmpc.jfmpc_1976_21] [PMID] [PMCID]
31. Gautam V, et al. Sensitivity pattern of Salmonella serotypes in Northern India. Brazilian Journal of Infectious Diseases 2002; 6: 281-287. [DOI:10.1590/S1413-86702002000600003] [PMID]
32. Nagshetty K, Channappa ST, Gaddad SM. Antimicrobial susceptibility of Salmonella Typhi in India. J Infect Dev Ctries. 2010 Mar 8;4(2):70-3. PMID: 20212336.
33. Patil N, Mule P. Sensitivity pattern of Salmonella typhi and paratyphi A isolates to chloramphenicol and other anti typhoid drugs: An in vitro study. Infect Drug Resist 2019;12:3217 25. [DOI:10.2147/IDR.S204618] [PMID] [PMCID]
34. Park K. Typhoid fever. In: Park's Textbook of Preventive and Social Medicine, 18th edn. Jabalpur: Bhanot, 2005: pp. 187-190.
35. Asghar, M.; Khan, T.A.; Séraphin, M.N.; Schimke, L.F.; Cabral-Marques, O.; Haq, I.U.; Farooqi, Z.-u.-R.; Campino, S.; Ullah, I.; Clark, T.G. Exploring the Antimicrobial Resistance Profile of Salmonella typhi and Its Clinical Burden. Antibiotics 2024, 13, 765. [DOI:10.3390/antibiotics13080765] [PMID] [PMCID]
36. Butt, M.H.; Saleem, A.; Javed, S.O.; Ullah, I.; Rehman, M.U.; Islam, N.; Tahir, M.A.; Malik, T.; Hafeez, S.; Hafeez, S. Rising XDR-typhoid fever cases in Pakistan: Are we heading back to the pre-antibiotic era? Front. Public Health 2022, 9:794868. [DOI:10.3389/fpubh.2021.794868] [PMID] [PMCID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.